Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

St Francis Holdings LLC

Neither a doctor nor a teaching hospital

Research payments

$1,047,761

273 payments

Through program year 2025, St Francis Holdings LLC is reported as receiving $1,047,761 in research payments, across 273 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $81,863 30
2024 Research $220,247 81
2023 Research $266,928 70
2022 Research $98,754 43
2021 Research $280,435 34
2020 Research $99,534 15

Breakdown

Who paid Research payments · program years 2020–2025
  1. Eli Lilly and Company $187,254 8 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $177,137 6 payments
  3. United Therapeutics Corporation $130,779 57 payments
  4. GlaxoSmithKline, LLC. $123,890 42 payments
  5. Chiesi USA, Inc. $118,641 41 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $118,420 37 payments
  7. Harmony Biosciences LLC $98,387 49 payments
  8. Paratek Pharmaceuticals, Inc. $74,943 22 payments
  9. Sanofi US Services Inc. $18,310 11 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis $118,630 43 payments
  2. A 52-Week, Randomised, Double-Blind, Double-Dummy, Parallel Group, Mul $103,655 34 payments
  3. Phase II PoCP $98,119 3 payments
  4. A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) $81,218 26 payments
  5. A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis $79,190 2 payments
  6. A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, & Tolerability of Oral Omadacycline in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex $74,943 22 payments
  7. A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tak-994 in Patients With Narcolepsy With Or Without Cataplexy (Narcolepsy Type 1 Or Narcolepsy Type 2) $67,537 17 payments
  8. A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $63,497 3 payments
  9. A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia $57,380 18 payments
  10. A Dose-Blind Extension Study With Double-Blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of Tak-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1) $49,283 18 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record